Form 8-K - Current report:
SEC Accession No. 0001683168-24-007685
Filing Date
2024-11-06
Accepted
2024-11-06 16:40:18
Documents
17
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 47378
2 STANDBY EQUITY PURCHASE AGREEMENT coeptis_ex1001.htm EX-10.1 265571
3 FORM OF CONVERTIBLE PROMISSORY NOTE coeptis_ex1002.htm EX-10.2 127550
4 REGISTRATION RIGHTS AGREEMENT coeptis_ex1003.htm EX-10.3 91462
  Complete submission text file 0001683168-24-007685.txt   861151

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE coep-20241101.xsd EX-101.SCH 3263
6 XBRL DEFINITION FILE coep-20241101_def.xml EX-101.DEF 26557
7 XBRL LABEL FILE coep-20241101_lab.xml EX-101.LAB 36481
8 XBRL PRESENTATION FILE coep-20241101_pre.xml EX-101.PRE 25181
19 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 5580
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 241431706
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)